Literature DB >> 19322953

The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor.

J S Markowitz1, C L DeVane, S Ramamoorthy, Hao-Jie Zhu.   

Abstract

The present study was undertaken to determine whether d-threo-(R,R)-methylphenidate (MPH) was exerting binding activity as an agonist or antagonist of 5-HT1A and 5-HT2B receptors. [35S]guanosine5'[gamma-thio]triphosphate ([35S]GTPgammaS) binding assay and field-stimulated Guinea pig ileum assay were used to determine 5-HT(1A) receptor agonism and antagonism activity of d-threo-(R,R)-MPH. The results suggested d-threo-(R,R)-MPH induced 5-HT(1A) receptor agonist activity at 100 microM. The Guinea pig ileum functional assay showed that d-threo-(R,R)-MPH produced agonist-like reduction of neurogenic twitch with an EC50 5.65 +/- 0.36 microM. At 30 microM concentrations, d-threo-(R,R)-MPH produced 171 +/- 4.24% of the relaxation relative to that caused by 0.12 microM 8-OH-DPAT. However, d-threo-(R,R)-MPH exhibited no significant pharmacological activity in rat stomach fundus 5-HT(2B) receptor functional assay. Thus, d-threo-(R,R)-MPH appears to act as a selective 5-HT(1A) receptor agonist in vitro. It is speculated that the activation of 5-HT(1A) receptor might play a partial role in d-threo-(R,R)-MPH mediated dopamine (DA) release in the brain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322953

Source DB:  PubMed          Journal:  Pharmazie        ISSN: 0031-7144            Impact factor:   1.267


  10 in total

Review 1.  The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities.

Authors:  Stephen V Faraone
Journal:  Neurosci Biobehav Rev       Date:  2018-02-08       Impact factor: 8.989

Review 2.  Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

Authors:  Fatemeh Farjadian; Amir Ghasemi; Omid Gohari; Amir Roointan; Mahdi Karimi; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2018-11-19       Impact factor: 5.307

3.  New Formulations of Stimulants: An Update for Clinicians.

Authors:  Ronald Steingard; Sarper Taskiran; Daniel F Connor; John S Markowitz; Mark A Stein
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-04-30       Impact factor: 2.576

4.  PharmGKB summary: methylphenidate pathway, pharmacokinetics/pharmacodynamics.

Authors:  Tyler Stevens; Katrin Sangkuhl; Jacob T Brown; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-08       Impact factor: 2.089

Review 5.  In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder.

Authors:  Edna Grünblatt; Jasmin Bartl; Zoya Marinova; Susanne Walitza
Journal:  J Neural Transm (Vienna)       Date:  2012-07-26       Impact factor: 3.575

Review 6.  Lifetime evolution of ADHD treatment.

Authors:  Federico Mucci; Barbara Carpita; Giovanni Pagni; Alessandra Della Vecchia; Sarah Bjedov; Andrea Pozza; Donatella Marazziti
Journal:  J Neural Transm (Vienna)       Date:  2021-05-15       Impact factor: 3.850

7.  Methylphenidate off-label use and safety.

Authors:  Thierry Trenque; Emmanuelle Herlem; Malak Abou Taam; Moustapha Drame
Journal:  Springerplus       Date:  2014-06-07

Review 8.  Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.

Authors:  Rafał R Jaeschke; Ewelina Sujkowska; Magdalena Sowa-Kućma
Journal:  Psychopharmacology (Berl)       Date:  2021-08-26       Impact factor: 4.530

Review 9.  Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.

Authors:  Cintya Nirvana Dutta; Leonardo Christov-Moore; Hernando Ombao; Pamela K Douglas
Journal:  Front Hum Neurosci       Date:  2022-09-26       Impact factor: 3.473

10.  Cerebral blood flow predicts differential neurotransmitter activity.

Authors:  Juergen Dukart; Štefan Holiga; Christopher Chatham; Peter Hawkins; Anna Forsyth; Rebecca McMillan; Jim Myers; Anne R Lingford-Hughes; David J Nutt; Emilio Merlo-Pich; Celine Risterucci; Lauren Boak; Daniel Umbricht; Scott Schobel; Thomas Liu; Mitul A Mehta; Fernando O Zelaya; Steve C Williams; Gregory Brown; Martin Paulus; Garry D Honey; Suresh Muthukumaraswamy; Joerg Hipp; Alessandro Bertolino; Fabio Sambataro
Journal:  Sci Rep       Date:  2018-03-06       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.